Imprime PGG (Imprime) plus pembrolizumab (PEM): a phase 2 immunotherapeutic combination in patients selected for an Imprime-specific biomarker
- Resource Type
- Journal
- Authors
- O'Day, Steven; Bose, Nandita; Uhlik, Mark; Prathikanti, Radha; Harrison, Ben; Leonardo, Steven; Huhn, Richard; Ottoson, Nadine; Qiu, Xiaohong; Walsh, Richard; Mattson, Paulette; Ma, Mable; Ertelt, Katie; Lowe, Jamie; Gargano, Michele A.; Chisamore, Michael; Osterwalder, Bruno; Graff, Jeremy
- Source
- MOLECULAR CANCER THERAPEUTICS; JAN 2018, 17 1, 2p. Supplement: S
- Subject
- Language
- English
- ISSN
- 15388514